Navigating the CMS 14-Day Rule in Biomarker Testing

David L. Rimm, MD, PhD; Roy S. Herbst, MD, PhD

Video Categories: PMO Interview with the Innovator Series: Volume 12 and Video Library

Drs. David Rimm and Roy Herbst review the problems with the CMS “14-Day Rule” since some of the multigene panel biomarker tests require 21 days or longer to complete.

Related Videos

December 12, 2016

New Effective Targets

Sunil Verma, MD, MSEd, FRCPC discusses new classes of therapies for HR+ Breast Cancer.

December 18, 2018

Financial Constraints to Molecular Biomarker Testing

Drs. David Rimm and Roy Herbst discuss the challenges of reimbursement by payers and the costs to pathology department of molecular biomarker testing, especially immunohistochemistry and DNA testing.